Abstract

BackgroundCancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that acts as a prognostic marker for several human malignancies. In this study, we investigated the clinical significance of CIP2A and its function in nasopharyngeal carcinoma (NPC).MethodsQuantitative RT-PCR, western blot, and immunohistochemistry analyses were used to quantify CIP2A expression in NPC cell lines and clinical samples. Kaplan-Meier curves were used to estimate the association between CIP2A expression and patient survival. The functional role of CIP2A in NPC cell lines was evaluated by small interfering RNA-mediated depletion of the protein followed by analyses of cell proliferation and xenograft growth.ResultsCIP2A levels were upregulated in NPC cell lines and clinical samples at both the mRNA and protein levels (P < 0.01). Patients with high CIP2A expression had poorer overall survival (HR, 1.98; 95% CI, 1.16-3.34; P = 0.01) and poorer disease-free survival (HR, 1.68; 95% CI, 1.07-2.62; P = 0.02) rates than patients with low CIP2A expression. In addition, CIP2A expression status was an independent prognostic indicator for NPC patients. The depletion of CIP2A expression inhibited c-Myc protein expression in NPC cell lines, suppressed cell viability, colony formation, and anchorage-independent growth in vitro, and inhibited xenograft tumor growth in vivo.ConclusionsOur data demonstrate that high CIP2A expression in patients was associated with poor survival in NPC, and depletion of CIP2A expression inhibited NPC cell proliferation and tumor growth. Thus, these results warrant further investigation of CIP2A as a novel therapeutic target for the treatment of NPC.

Highlights

  • Nasopharyngeal carcinoma (NPC) is an epithelial malignancy of the nasopharynx, and global statistics obtained for different world regions reveal that its distribution is extremely unbalanced, with the highest incidence rates occurring in Southern China [1,2]

  • These results suggest that Cancerous inhibitor of protein phosphatase 2A (CIP2A) is upregulated in nasopharyngeal carcinoma (NPC)

  • Representative staining of CIP2A in NPC tissue is shown in Figure 2A-H, and positive staining of CIP2A was mainly observed in the cytoplasm

Read more

Summary

Introduction

Nasopharyngeal carcinoma (NPC) is an epithelial malignancy of the nasopharynx, and global statistics obtained for different world regions reveal that its distribution is extremely unbalanced, with the highest incidence rates occurring in Southern China [1,2]. Cancerous inhibitor of protein phosphatase 2A (CIP2A), known as KIAA1524 and p90, is a recently identified human oncoprotein that inhibits the degradation of c-MYC by inhibiting the protein phosphatase 2A (PP2A)-mediated dephosphorylation of MYC at serine 62 [6,7,8]. The clinical significance and biological function of CIP2A in NPC has not been thoroughly investigated to date. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that acts as a prognostic marker for several human malignancies. We investigated the clinical significance of CIP2A and its function in nasopharyngeal carcinoma (NPC)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call